Business Standard

World Coronavirus Dispatch: Remdesivir gets lukewarm endorsement

US deaths top 1,000 for fourth day, Google suffers first revenue decline, Spain's GDP shrinks 18.5% and other pandemic-related news across the globe

remdesivir, coronavirus, drugs, covid, pharma
Premium

The effectiveness of most interventions with remdesivir is uncertain

Yuvraj Malik New Delhi
Remdesivir gets lukewarm endorsement: Gilead Sciences’s remdesivir is worth prescribing for patients with severe Covid-19, though evidence of its benefits remains inconclusive, according to a panel of international experts convened by the British Medical Journal. The effectiveness of most interventions with remdesivir is uncertain because most of the trials so far have been small and have limitations, the authors said in a review for the journal. Read more here

Let’s look at the global statistics: 


Total Confirmed Cases: 17,039,160


Change Over Yesterday: 276,590

Total Deaths: 673,568

Total Recovered: 10,151,894

Nations hit with most cases: US (4,495,015), Brazil (2,610,102), India

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in